Clinical trial
A Phase II Optimization Study of BMS068645 and Sestamibi Planar Imaging
NCT00162071 · Forest Laboratories, Industry · Terminated
Key facts
| NCT number | NCT00162071 |
|---|---|
| Title | A Phase II Optimization Study of BMS068645 and Sestamibi Planar Imaging |
| Official title | "A Phase II Open-Label, Non-Randomized, Single-Center Trial to Determine the Optimal Myocardial Perfusion Image Acquisition Time Following BMS068645 Administration |
| Lead sponsor | Forest Laboratories, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cardiovascular Disease, Ischemic Heart Disease |
| Intervention type | Drug |
| Interventions | apadenoson |
| Enrollment | 20 |
| Start date | Jul 1, 2005 |
| Primary completion | Mar 1, 2006 |
| First posted | Sep 13, 2005 |
| Last update posted | Feb 1, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: